Hematologic Malignancy
Acute Lymphoblastic Leukemia
CI-CAN-00000400ALLExplore in graph →
Hematologic547 active trials12 approved drugs43 evidence items
- NCIt
- C3167
- DOID
- 9952
- MeSH
- D054198
- Other
- 3 more codes
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000400ALLExplore in graph →
Clinical trials
2,037 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (267)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07346105 | Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies | available | — | — | Orca Biosystems, Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05738538 | Expanded Access to Ziftomenib | available | — | — | Kura Oncology, Inc.INDUSTRY | 0 | Jun 29, 2026 | clinicaltrials |
| Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel |
| available |
| — |
| — |
| Kite, A Gilead CompanyINDUSTRY |
| 1 |
| Apr 8, 2026 |
| clinicaltrials |
| NCT06799221 | Expanded Access Program for OOS Obe-cel | available | — | — | Autolus LimitedINDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03123029 | Expanded Access to Venetoclax | available | — | — | AbbVieINDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials